NDATOPICALCREAMPriority Review
Approved
Nov 1952
Lifecycle
LOE Approaching
Competitive Pressure
30/100
Data completeness
1/8 — Limited
Priority Review
Drug data last refreshed 20h ago · AI intelligence enriched 2w ago
AI summarySynthesized from FDA + DailyMed + ClinicalTrials.gov data
BENOQUIN (monobenzone) is a topical cream depigmenting agent approved in 1952 for treating vitiligo and other hyperpigmentation disorders. The mechanism of action involves inhibition of melanin synthesis, making it useful for patients seeking to depigment affected areas rather than repigment them. It represents a niche therapeutic option in dermatology with a long-established safety and efficacy profile.
LOE Approaching
As a legacy product approaching loss of exclusivity with moderate competitive pressure (30%), the brand team is likely focused on defensive positioning and operational efficiency rather than growth expansion.
Mechanism of Action
Mechanism of action data is being enriched from DailyMed and FDA sources. Check back soon for updated drug intelligence.
Indications
Indication data is being enriched from DailyMed and FDA labeling. Check back soon for approved therapeutic uses.
Career Relevance
Working on BENOQUIN offers limited growth opportunities given its LOE-approaching status and zero currently linked job openings, but provides valuable experience in legacy product management, specialty dermatology, and defensive commercial strategy. This role is best suited for professionals seeking stability and operational expertise rather than launch excitement or market expansion challenges.
Brand Manager
Worked on BENOQUIN at Bausch + Lomb? Share your interview experience or compensation data (+7 days Pro)
Data Sources
- Drug label: DailyMed / FDA
- Clinical trials: ClinicalTrials.gov
- Patent data: FDA Orange Book
- Spending data: CMS Medicare
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.